Graft Polymer UK PLC
LSE:GPL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (0.5), the stock would be worth GBX-0.01 (107% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -6.7 | GBX0.17 |
0%
|
| Industry Average | 0.5 | GBX-0.01 |
-107%
|
| Country Average | 0.2 | GBX-0.01 |
-103%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
G
|
Graft Polymer UK PLC
LSE:GPL
|
3.8m GBP | -6.7 | -1.4 | |
| JP |
|
Shin-Etsu Chemical Co Ltd
TSE:4063
|
13.2T JPY | 22.7 | 27.8 | |
| US |
|
Sherwin-Williams Co
NYSE:SHW
|
78.8B USD | 23.9 | 30.7 | |
| US |
|
Ecolab Inc
NYSE:ECL
|
73.2B USD | 34.4 | 35.3 | |
| JP |
Y
|
Yasuhara Chemical Co Ltd
TSE:4957
|
10.8T JPY | -68 | 10.5 | |
| CN |
|
Wanhua Chemical Group Co Ltd
SSE:600309
|
280.3B CNY | 16.5 | 21.3 | |
| CH |
|
Givaudan SA
SIX:GIVN
|
25.7B CHF | 32.8 | 24 | |
| DK |
|
Novozymes A/S
CSE:NZYM B
|
165.6B DKK | 59.7 | 54.8 | |
| IN |
|
Asian Paints Ltd
NSE:ASIANPAINT
|
2.3T INR | 48 | 60.8 | |
| US |
|
PPG Industries Inc
NYSE:PPG
|
24B USD | 12.6 | 15.2 | |
| CH |
|
Sika AG
F:SIKA
|
19.9B EUR | 20 | 17.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.1 |
| Median | 0.2 |
| 70th Percentile | 0.4 |
| Max | 901.8 |
Other Multiples
Graft Polymer UK PLC
Glance View
Graft Polymer (UK) Ltd. is a holding company, which comprises polymer modification and drug delivery systems developments. The firm's primary business comprises polymer modification and drug delivery systems developments. The company develops range of products, including grafted polymer modifiers; nano-structured and crosslinking polymer alloys; and a variety of delivery vehicles for pharma and bio applications. Its products fall into the category of standard products, such as Polypropylene-based composites, Polyamide-based composites, and other composites; custom made products; and innovative products, such as GRAFTALLOY, GRAFTAKIT, GRAFTAMER TRC, and GRAFTAMER VTR. The firm provides three main types of modification solutions, including Graft/Block copolymers, Polymeric Nano-Structured Alloys and Crosslinking Master batches.
